Inventor · disambiguated record
Wieslaw M. Cholody
Also filed as: CHOLODY WIESLAW M · CHOLODY WIESLAW MAREK
11 granted patents·129 citations·filing 1991–2016
88Inventor score
Files withCHOLODY WIESLAW M2ONCOARENDI THERAPEUTICS SP Z O O2US HEALTH2AVALON PHARMACEUTICALS1BRITISH TECH GROUP1
Top patents by PatentIndex Score
11 records- 0193US8129519B2Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereofCHOLODY WIESLAW M·Filed 2008·Granted Mar 6, 2012·97 cites·6 claims
- 0273US9095575B2Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agentsONCOARENDI THERAPEUTICS SP Z O O·Filed 2014·Granted Aug 4, 2015·2 cites·16 claims
- 0369US6664263B21,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activityUS HEALTH·Filed 2001·Granted Dec 16, 2003·8 cites·20 claims
- 0468US9388192B2Benzimidazole derivatives as Kinase InhibitorsSELVITA SA·Filed 2013·Granted Jul 12, 2016·3 cites·19 claims
- 0565US7094791B2Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereofAVALON PHARMACEUTICALS·Filed 2003·Granted Aug 22, 2006·5 cites·22 claims
- 0661US5231100AAntineoplastic modified imidazoacridinesBRITISH TECH GROUP·Filed 1991·Granted Jul 27, 1993·8 cites·14 claims
- 0754US9120754B2Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereofCHOLODY WIESLAW M·Filed 2012·Granted Sep 1, 2015·0 cites·19 claims
- 0853US8981114B2Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agentsONCOARENDI THERAPEUTICS SP Z O O·Filed 2014·Granted Mar 17, 2015·0 cites·15 claims
- 0951US9446021B2Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereofDOGWOOD PHARMACEUTICALS INC·Filed 2015·Granted Sep 20, 2016·0 cites·15 claims
- 1043US5508289ABis-acridone chemotherapeutic derivativesUS HEALTH·Filed 1994·Granted Apr 16, 1996·6 cites·28 claims
- 1132US10174013B2Benzimidazole derivatives as kinase inhibitorsSELVITA S A·Filed 2016·Granted Jan 8, 2019·0 cites·13 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →